SAN DIEGO, March 10, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax has an exclusive license to these therapeutic vaccines from Memorial Sloan Kettering Cancer Center (MSKCC). In December 2015 MabVax received authorization from the U.S. Food and Drug Administration (FDA) to proceed with initiation of a Phase I clinical trial with HuMab-5B1 as a therapeutic treatment for pancreatic cancer and patient enrollment in the Phase I clinical trial is expected to begin at multiple investigational sites in the first quarter of 2016. In February 2016, MabVax announced that the FDA had provided authorization to proceed with 89Zr-HuMab-5B1, utilizing the company's fully human antibody product as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. We expect patient enrollment for the new generation PET scan cancer imaging agent to begin in early 2016. MabVax also has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials. Additional information is available at www.mabvax.com.
Senior Vice President
SOURCE MabVax Therapeutics Holdings, Inc.